Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 0.83 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.83 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.83 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.83 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.83 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.83 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.74 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23541015 | 0.98 | F2 (0.83) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL1034406 | 0.98 | F2 (0.83) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL7091092 | 0.94 | F2 (0.76) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL7317832 | 0.92 | F2 (0.79) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL34433860 | 0.91 | F2 (0.83) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL14543642 | 0.91 | F2 (1.00) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL23541143 | 0.89 | F2 (1.00) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL14543821 | 0.88 | F2 (1.00) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL28553185 | 0.86 | F2 (1.00) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7449474 | 0.86 | F2 (0.89) | F2PRSS1PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3897600-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | Auransa Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021180008-A1 | TRI-AROMATIC RING COMPOUND CONTAINING UREA STRUCTURE AND USE THEREOF | 暨南大学 | 2021-09-16 | — | — | WO | disclosed |
| WO-2020132636-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132636-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20130281462-A1 | ARYL DIAMIDINES AND PRODRUGS THEREOF FOR TREATING MYOTONIC DYSTROPHY | UNIVERSITY OF OREGON (US) | 2013-10-24 | — | — | US | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| WO-2003000693-A1 | IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| US-5804097-A | HAVING HIGH FLOW VISCOSITY, GOOD MISCIBILITY WITH OTHER LIQUID CRYSTALS | BASF AKTIENGSELLSCHAFT (DE) | 1998-09-08 | — | — | US | disclosed |
| EP-0720641-B1 | LIQUID-CRYSTALLINE COMPOUNDS | BASF AG (DE) | 1998-08-12 | — | — | EP | disclosed |
| EP-0720641-A1 | LIQUID-CRYSTALLINE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995022586-A1 | NEW POLYMERISABLE LIQUID CRYSTAL COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1995-08-24 | — | — | WO | disclosed |
| WO-1995008604-A1 | LIQUID-CRYSTALLINE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1995-03-30 | — | — | WO | disclosed |
| EP-0355830-A2 | Liquid crystal composition and use thereof | DAISO CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| US-4853383-A | β-blocking substituted imidazoles | MERCK & CO., INC. (US) | 1989-08-01 | — | — | US | disclosed |
| EP-0306919-A2 | Liquid crystalline compounds and process for production thereof | DAISO CO., LTD. (JP) | 1989-03-15 | — | — | EP | disclosed |
| US-4642311-A | β-adrenergic blocking imidazolylphenoxy propanolamines | MERCK & CO., INC. (US) | 1987-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | MALT1, SLC38A7, SLC7A1 | F2 1975/4885PRSS1 1468/4885PRSS2 2579/4885 |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | DPYD, TYMP, GOT1 | F2 2382/4885PRSS1 2086/4885PRSS2 3033/4885 |
| US-20130281462-A1 | ARYL DIAMIDINES AND PRODRUGS THEREOF FOR TREATING MYOTONIC DYSTROPHY | HTT, ATXN2, SNRPD2 | F2 3936/4885PRSS1 1050/4885PRSS2 577/4885 |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, GRN | F2 3712/4885PRSS1 2062/4885PRSS2 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.